Cynata Therapeutics Ltd
CYP
Company Profile
Business description
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.
Contact
100 Cubitt Street
Level 3
CremorneVIC3121
AUST: +61 370676940
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
2
Stocks News & Analysis
stocks
Strong finish to the year for overvalued ASX share
A great fiscal 2025 but investors are ahead of themselves.
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,080.70 | 39.80 | -0.44% |
| CAC 40 | 7,749.39 | 14.55 | 0.19% |
| DAX 40 | 23,718.45 | 88.68 | -0.37% |
| Dow JONES (US) | 45,711.34 | 196.39 | 0.43% |
| FTSE 100 | 9,242.53 | 21.09 | 0.23% |
| HKSE | 25,938.13 | 304.22 | 1.19% |
| NASDAQ | 21,879.49 | 80.79 | 0.37% |
| Nikkei 225 | 43,459.29 | 184.52 | -0.42% |
| NZX 50 Index | 13,253.73 | 27.41 | -0.21% |
| S&P 500 | 6,512.61 | 17.46 | 0.27% |
| S&P/ASX 200 | 8,803.50 | 37.40 | -0.42% |
| SSE Composite Index | 3,807.29 | 19.55 | -0.51% |